The search for effective interventions against Bundibugyo virus disease is gaining momentum in the Democratic Republic of the Congo (DRC), with two additional vaccine candidates set to enter an ongoing clinical trial. The move marks the first time vaccines specifically developed against Bundibugyo virus will be evaluated during an outbreak. The candidates, ChAdOx1, developed by the University of Oxford in collaboration with the Serum Institute of India, and Moderna's mRNA-1469, have received recommendations for further clinical evaluation from an independent World Health Organization (WHO) technical advisory group.

Both will join the Tumaini trial following national regulatory approvals. Led by the DRC's Institut National de Recherche Biomédicale, the trial is designed to evaluate multiple vaccine candidates using a ring-vaccination strategy. This approach prioritizes contacts of…